Step 1 Treatment for Asthma in Children Aged 6-11 Years (GINA Guidelines)
For children aged 6-11 years with asthma, GINA recommends as-needed low-dose inhaled corticosteroid (ICS) taken whenever a short-acting beta-agonist (SABA) is used, rather than SABA alone. This represents a fundamental shift away from using SABA monotherapy even for the mildest asthma 1, 2.
Preferred Treatment Approach
The current GINA strategy for this age group at Step 1 consists of:
- No daily controller medication
- As-needed reliever therapy: Low-dose ICS plus SABA taken together whenever symptoms occur 1
This approach prioritizes safety by ensuring that every time a child uses a bronchodilator for symptom relief, they also receive anti-inflammatory treatment. The rationale is that SABA-only treatment has been associated with increased risk of exacerbations and asthma-related deaths, even in mild disease 2, 3.
Important Implementation Details
Key difference from adolescents/adults: Unlike patients ≥12 years old, GINA does not recommend ICS/formoterol as the preferred reliever for children 6-11 years at Step 1 1. The preferred track for this age group uses separate ICS and SABA inhalers taken concomitantly as needed.
Practical Considerations:
- No combined ICS/SABA products exist in most markets, requiring two separate inhalers 1
- Parents must be educated to give both inhalers together whenever the child has symptoms
- This is an off-label use in many jurisdictions, requiring shared decision-making with families 1
Alternative Approach (If Preferred Strategy Not Feasible)
If the concomitant ICS/SABA strategy is not practical or acceptable, the alternative is:
- SABA alone as needed (traditional approach)
- However, this is now considered less safe and should only be used when the preferred option cannot be implemented 1, 2
When to Move Beyond Step 1
Step up to Step 2 (daily low-dose ICS) if the child has:
- Asthma symptoms or need for reliever therapy more than twice per week 4, 5
- Any nighttime awakening due to asthma
- Any activity limitation due to asthma
- History of severe exacerbations requiring oral corticosteroids
Critical Pitfalls to Avoid
Do not prescribe SABA alone for any child with asthma, even intermittent disease—this is the most significant change in recent GINA guidelines 2, 3
Ensure proper inhaler technique: Most children in this age group cannot use metered-dose inhalers (MDIs) without a spacer device 6. Use MDI with valved holding chamber (spacer) or consider dry powder inhalers for children who can generate adequate inspiratory flow
Monitor adherence closely: The as-needed ICS/SABA strategy requires parents to remember to give both medications together, which may be challenging 1
Reassess diagnosis if no response: If clear benefit is not seen within 4-6 weeks of appropriate treatment, reconsider the diagnosis or look for alternative causes of symptoms 4, 5
Evidence Strength and Guideline Evolution
The recommendation for ICS with every SABA use represents a 2019-2020 paradigm shift in GINA guidelines 1, 2. However, the evidence base is weaker in children 6-11 years compared to adolescents and adults, which is why GINA does not recommend ICS/formoterol as reliever therapy in this age group 1. Some national guidelines have not yet adopted this approach due to limited pediatric evidence 2.
The 2020 NAEPP guidelines present this as the preferred approach for Step 1 in children 5-11 years old, though they acknowledge it differs from traditional stepwise management 1.